Skip to main content

Table 1 Comparison of baseline characteristics amongst patients with TPMT, with NUDT15 and without any mutations

From: TPMT and NUDT15 polymorphisms in thiopurine induced leucopenia in inflammatory bowel disease: a prospective study from India

  TPMT mutated
(N = 5)
n (%)/ Median (IQR)
Wild Genotype
(N = 102)
n (%)/ Median (IQR)
P value NUDT15 mutated
(N = 13)
n (%)/ Median (IQR)
Wild Genotype
(N = 102)
n (%)/ Median (IQR)
P value
Age (years) 42 (16) 35.5 (22) 0.881 40 (19) 35.5 (22) 0.418
Male 1 (20%) 53 (51.9%) 0.162 7 (53.8%) 53 (51.9%) 0.898
Smoker (past or present) 0 16 (15.7%) 1.00 2 (15.4%) 16 (15.7%) 1.000
Alcohol use (past or present) 0 (100%) 24 (23.5%) 1.00 2 (15.4%) 24 (23.5%) 0.729
Body weight (kg) 55 (18) 55 (20) 0.915 54 (8) 55 (20) 0.407
Comorbidities 0 (0%) 14 (13.7%) 1.00 3 (23.1%) 14 (13.7%) 0.405
Recent Steroid Use (3 months) 2 (40%) 58 (56.9%) 0.652 7 (53.8%) 58 (56.9%) 1.000
Current 5-Aminosalisylate use 5 (100%) 97 (95.1) 1.000 12 (92.3%) 97 (95.1) 0.5214
Disease duration (months) 48.0 (138) 36 (41) 0.949 36 (62) 36 (41) 0.168
Hemoglobin (g/dL) 10.7 (4.81) 11.2 (2.93) 0.949 12.8 (2.35) 11.2 (2.93) 0.236
Total leucocyte count (× 106/L) 9700 (4080) 8950 (4400) 0.348 9700 (4750) 8950 (4400) 0.477
Platelet count (× 106/L) 354,000 (104,000) 323,500 (183,250) 0.327 292,000 (186,000) 323,500 (183,250) 0.516